Retinopathy of prematurity (ROP) is a vasoproliferative retinal disease that afflicts as much as 50% of all extremely low gestational age neonates (ELGANs, <1250g/<28 weeks) with approximately 5% condemned to a lifetime of blindness. Caffeine and NSAIDs have been shown to decrease the risk of severe ROP in ELGANs. However, the routes of administration and the timing of drug intervention remain debatable. We propose a novel approach combining topical ibuprofen or ketorolac with systemic caffeine to optimize their efficacy for prevention of oxygen-induced retinopathy (OIR). The overarching goal of this proposal is to investigate whether topical ocular ibuprofen or ketorolac potentiated with systemic caffeine decreases the incidence and/or severity of OIR in neonatal rats exposed to frequent, brief, clustered hyperoxia-hypoxia cycling.
Our specific aims are three-fold: 1) To identify the critical number of hyperoxic/hypoxic episodes that will result in upregulation of genes responsible for abnormal angiogenesis and severe OIR. We hypothesize that there is a critical number of hyperoxia/hypoxia cycles beyond which the developing retina will not recover;2) Using optimized preparations, we will determine if ibuprofen (Neoprofen) or a new preparation of ketorolac (Acuvail) administered topically as eye drops, with or without systemic caffeine citrate (Cafcit) exert protective effects on the retina at risk for severe OIR. We will also determine the dose-response of ibuprofen. We hypothesize that topical ibuprofen or ketotolac potentiated with systemic caffeine will provide long term efficacy and safety for prevention of OIR;and 3) To examine whether the protective effects of ibuprofen or ketorolac eye drops, potentiated with caffeine, are determined by timing of administration of the drug. We hypothesize that timing of drug administration in relation to the disease phase (vasoobliterative versus proliferative) is a major determinant of drug efficacy. We believe that once activated in the immature retina, the mechanisms for neovascularization are irreversible. Early identification and prevention is vital. Our proposed studies will aid in early identification of infants at risk.

Public Health Relevance

These proposed studies will use topical, non-invasive, NSAIDs (ibuprofen and ketorolac) complemented with systemic caffeine citrate to preserve normal retinal growth and development during oxidative stress in order to protect the immature retina. Data from these studies will form the rationale for a future clinical trial to prevent ROP, the most common cause of childhood blindness. ROP is the leading cause of childhood blindness and the epidemic is increasing. Current medications, such as intravitreal Avastin is highly invasive, causes retinal hemorrhage, retinal detachment, choroidal ruptures, etc., and may have adverse effects on associated retinal cells such as astrocyges and microglia. The need for other potential therapies is vital. The unique strategy proposed in these studies will provide an alternate approach and form the rationale for a future clinical trial.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD071594-02
Application #
8379422
Study Section
Special Emphasis Panel (ZHD1-DSR-A)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$124,297
Indirect Cost
$46,368
Name
Suny Downstate Medical Center
Department
Type
DUNS #
040796328
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Beharry, Kay D; Cai, Charles L; Henry, Michael M et al. (2017) Co-Enzyme Q10 and n-3 Polyunsaturated Fatty Acid Supplementation Reverse Intermittent Hypoxia-Induced Growth Restriction and Improved Antioxidant Profiles in Neonatal Rats. Antioxidants (Basel) 6:
Vali, Payam; Chandrasekharan, Praveen; Rawat, Munmun et al. (2017) Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. J Am Heart Assoc 6:
Tu, Chengjian; Shen, Shichen; Sheng, Quanhu et al. (2017) A peptide-retrieval strategy enables significant improvement of quantitative performance without compromising confidence of identification. J Proteomics 152:276-282
Tu, Chengjian; Mojica, Wilfrido; Straubinger, Robert M et al. (2017) Quantitative proteomic profiling of paired cancerous and normal colon epithelial cells isolated freshly from colorectal cancer patients. Proteomics Clin Appl 11:
Tan, Jeffrey J; Cai, Charles L; Shrier, Eric M et al. (2017) Ocular Adverse Effects of Intravitreal Bevacizumab Are Potentiated by Intermittent Hypoxia in a Rat Model of Oxygen-Induced Retinopathy. J Ophthalmol 2017:4353129
Beharry, Kay D; Cai, Charles L; Valencia, Gloria B et al. (2017) Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development. Prostaglandins Other Lipid Mediat :
Tu, Chengjian; Li, Jun; Shen, Shichen et al. (2016) Performance Investigation of Proteomic Identification by HCD/CID Fragmentations in Combination with High/Low-Resolution Detectors on a Tribrid, High-Field Orbitrap Instrument. PLoS One 11:e0160160
Beharry, Kay D; Valencia, Gloria B; Lazzaro, Douglas R et al. (2016) Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity. Semin Perinatol 40:189-202
Tu, Chengjian; Bu, Yahao; Vujcic, Marija et al. (2016) Ion Current-Based Proteomic Profiling for Understanding the Inhibitory Effect of Tumor Necrosis Factor Alpha on Myogenic Differentiation. J Proteome Res 15:3147-57
Shen, Shichen; Jiang, Xiaosheng; Li, Jun et al. (2016) Large-Scale, Ion-Current-Based Proteomic Investigation of the Rat Striatal Proteome in a Model of Short- and Long-Term Cocaine Withdrawal. J Proteome Res 15:1702-16

Showing the most recent 10 out of 40 publications